HLA-DPA1, major histocompatibility complex, class II, DP alpha 1, 3113
N. diseases: 139; N. variants: 67
Source: ALL
Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1.000 | 0.120 | 6 | 33080863 | stop gained | A/C;G;T | snv | 2.4E-05; 0.25 |
|
Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases | 0.010 | 1.000 | 1 | 2000 | 2000 | |||||||
|
0.925 | 0.240 | 6 | 33080884 | missense variant | A/G | snv | 0.18 | 0.25 |
|
Pathological Conditions, Signs and Symptoms; Infections; Respiratory Tract Diseases; Immune System Diseases; Chemically-Induced Disorders; Otorhinolaryngologic Diseases | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||||
|
1.000 | 0.080 | 6 | 33075743 | intron variant | C/G | snv | 0.14 |
|
Skin and Connective Tissue Diseases; Immune System Diseases | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||||
|
0.925 | 0.080 | 6 | 33073957 | intron variant | T/C | snv | 0.12 |
|
Respiratory Tract Diseases | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Skin and Connective Tissue Diseases; Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Infections; Nervous System Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Digestive System Diseases; Infections | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Pathological Conditions, Signs and Symptoms | 0.010 | < 0.001 | 1 | 2011 | 2011 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Pathological Conditions, Signs and Symptoms; Digestive System Diseases | 0.010 | < 0.001 | 1 | 2011 | 2011 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Skin and Connective Tissue Diseases; Immune System Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Digestive System Diseases; Infections | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.701 | 0.440 | 6 | 33065245 | 3 prime UTR variant | A/G | snv | 0.29 |
|
Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Immune System Diseases | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.925 | 0.080 | 6 | 33077781 | intron variant | G/A | snv | 0.32 |
|
Digestive System Diseases; Infections | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
1.000 | 0.240 | 6 | 33080884 | missense variant | ATG/GTA | mnv |
|
Pathological Conditions, Signs and Symptoms; Infections; Respiratory Tract Diseases; Immune System Diseases; Chemically-Induced Disorders; Otorhinolaryngologic Diseases | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||||||
|
0.925 | 0.120 | 6 | 33077921 | intron variant | G/A | snv | 9.5E-02 |
|
Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Nervous System Diseases | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||||
|
1.000 | 0.080 | 6 | 33080689 | stop gained | G/T | snv |
|
Digestive System Diseases; Infections | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||||||
|
1.000 | 0.080 | 6 | 33080914 | missense variant | C/G | snv | 0.31 | 0.38 |
|
Digestive System Diseases; Infections | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
|
1.000 | 0.080 | 6 | 33080917 | missense variant | A/G | snv | 0.30 | 0.38 |
|
Digestive System Diseases; Infections | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
|
0.827 | 0.320 | 6 | 33082502 | intron variant | A/G | snv | 0.40 |
|
Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.827 | 0.320 | 6 | 33082502 | intron variant | A/G | snv | 0.40 |
|
Pathological Conditions, Signs and Symptoms; Neoplasms | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||||
|
0.827 | 0.320 | 6 | 33082502 | intron variant | A/G | snv | 0.40 |
|
Immune System Diseases | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||||
|
0.925 | 0.120 | 6 | 33081917 | intron variant | C/T | snv | 4.0E-02 |
|
Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Nervous System Diseases | 0.010 | 1.000 | 1 | 2016 | 2016 |